A double-blind, placebo-controlled human trial, published in the New England Journal of Medicine, found cannabidiol can decrease the frequency of convulsive seizures. 120 patients with Dravet syndrome were given orally administered cannabinoids. During the 14-week study, the cannabidiol groups average seizure frequency per month decreased from 12.4 to 5.9. On average, the change in seizure frequency amounted to a 39% decrease for the cannabidiol group patients, compared with a roughly 13% decrease among the placebo group.
Amazingly, as we’ve already seen from anecdotal results, five percent of the children became entirely seizure-free during the 14-week study, and when considering 59 out of the 120 were on a placebo, is an astounding result.